New lysine methyltransferase drug targets in cancer.
Tobias
T
Wagner
Manfred
M
Jung
D000071221:Enhancer of Zeste Homolog 2 Protein; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006649:Histocompatibility Antigens / Q000378:metabolism; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D008780:Methyltransferases / Q000037:antagonists & inhibitors / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D063151:Polycomb Repressive Complex 2 / Q000037:antagonists & inhibitors / Q000378:metabolism
D004791:Enzyme Inhibitors; D006649:Histocompatibility Antigens; C473477:DOT1L protein, human; D000076983:Histone Methyltransferases; D008780:Methyltransferases; C445405:EHMT2 protein, human; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D011495:Histone-Lysine N-Methyltransferase; D063151:Polycomb Repressive Complex 2; C540312:SETD7 protein, human; C512569:SMYD2 protein, human